echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In the first half of 2019, pharmaceutical companies with outstanding performance scale and growth

    In the first half of 2019, pharmaceutical companies with outstanding performance scale and growth

    • Last Update: 2019-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network industry trends] with the disclosure of China Daily entering the intensive period, scores of pharmaceutical enterprises in the first half of the year have also been published Data statistics show that as of August 1, 31 out of 307 pharmaceutical companies have published semi annual reports or performance bulletins, and another 125 companies have published performance forecasts, of which 32 have maintained a growth rate of more than 20% According to the public information, the author selects the enterprises with the largest performance scale, the highest growth rate in the first half of the year and the high growth rate in three consecutive quarters For the time being, the performance scale is the first: Mindray medical is expected to make more than 2.433 billion yuan in the first half of the year According to the semi annual performance forecast for 2019 issued by the company on July 11, during the reporting period, the company's main business income achieved steady growth, and the emerging business continued to make efforts to drive the company's overall business income to show a steady and sustained growth trend In addition, the continuous improvement of product market recognition, domestic and international marketing expansion and localization system help the company effectively achieve customer base breakthrough, and promote the company's sales in domestic and overseas markets to continue to grow At the same time, the company strengthens internal management, improves operating efficiency, and its operating performance continues to show a healthy and good growth trend High growth rate: it is understood that Tianyu has revised the performance forecast once, and the revised net profit is expected to reach 262 million, an increase of 545.93% over the same period of last year According to the announcement, during the reporting period, the company actively implemented its annual business objectives, with stable growth in its main business and large growth in its operating revenue The industry believes that the company's core product, Shatin, has abundant orders in hand, and its production capacity has grown at a rate of more than 50%, with a strong momentum The performance is expected to maintain high-speed growth Three consecutive quarters of high growth: Tianyu Co., Ltd had three consecutive quarters of high growth, and the outstanding performance is still Tianyu Co., Ltd In 2019, the net profit increased 529.73% year-on-year, 662.24% in the second quarter and 1530.11% in the fourth quarter, with an amazing growth rate According to the public information, Tianyu mainly produces pharmaceutical intermediates and APIs such as cardiovascular and cerebrovascular drugs, hypoglycemic drugs, blood lipid lowering drugs, anticoagulant drugs and antiasthmatic drugs In the first half of 2019, some of these companies with sustained and high growth in market performance were eye-catching in recent years, among which Beijing New Pharmaceutical Co., Ltd gained 15.89% in July In addition, Zhifei biology rose 8.93%, and kailitai rose 7.09% Beijing New Pharmaceutical Co., Ltd recently disclosed the semi annual report performance express that in the first half of 2019, the company achieved a total operating revenue of about 1.859 billion yuan, a year-on-year increase of 31.92%; the net profit attributable to shareholders of listed companies was 326 million yuan, a year-on-year increase of 52.89% On July 3, the first half of 2019 performance forecast released by Zhifei biology showed that the company's net profit in the reporting period is expected to reach 1.058-1.262 billion yuan, with a year-on-year growth rate of 55% - 85%, and a year-on-year profit of 682 million yuan According to the performance forecast released by kailitai, it is estimated that the net profit in the first half of 2019 will be 140-160 million yuan, an increase of 30% - 50% year on year In general, in the first half of this year, affected by the implementation of drug volume procurement, the overall performance of the pharmaceutical industry was flat, with a few enterprises showing outstanding performance According to the analysis of the insiders, in the second half of 2019, with the implementation of new policies in the areas of new round of drug procurement, centralized procurement of consumables, and adjustment of medical insurance catalog, there will be differentiation between the pharmaceutical industry segments.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.